ACE2 Polypeptid

European patent · EP2543724 · In force

Register entry

Publication number
EP2543724
Application number
EP12165189
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jun 12, 2008
Published
Jan 9, 2013
Granted
Mar 21, 2018
Protection ends at the latest
Jun 11, 2028
Next annual fee due
Jun 30, 2027
IPC classes
C12N 9/64 (2006.01)
Priority
AT 9132007 12.06.2007
EP 08450052 08.04.2008
Divided from
EP08756821
Filing language
German
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jul 1, 2026

    Next annual fee due on

    Next annual fee due on
    30.06.2026 → 30.06.2027

    Published in Swissreg on 01.07.2026

  2. Jul 1, 2025

    Next annual fee due on

    Next annual fee due on
    30.06.2025 → 30.06.2026

    Published in Swissreg on 01.07.2025

  3. Jul 1, 2024

    Change

    Published in Swissreg on 01.07.2024

  4. Jul 1, 2023

    Change

    Published in Swissreg on 01.07.2023

  5. Jul 1, 2022

    Change

    Published in Swissreg on 01.07.2022

  6. Jun 1, 2018

    Agent entered

    Representative
    Isler & Pedrazzini AG, Postfach 1772, 8027 Zürich

    Published in Swissreg on 01.06.2018

  7. Mar 21, 2018

    Granted

    Published in Swissreg on 21.03.2018

Parties

Holder

Apeiron Biologics AG

Campus-Vienna-Biocenter 5, 1030 Wien, AT

Agent

Isler & Pedrazzini AG

Postfach 1772, 8027 Zürich

Inventor

Schuster, Manfred

2191 Schrick, AT

Loibner, Hans

1230 Wien, AT

Janzek-Hawlat, Evelyne

1230 Wien, AT

Peball, Bernhard

1070 Wien, AT

Stranner, Stefan

1230 Wien, AT

Wagner, Bettina

2700 Wiener Neustadt, AT

Weik, Robert

2724 Hohe Wand-Stollhof, AT

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.